A Phase I Trial of CBT-1 in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Doxorubicin (Primary) ; Tetrandrine (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- Sponsors CBA Pharma
- 28 Jun 2017 Planned End Date changed from 1 Dec 2019 to 1 Sep 2020.
- 28 Jun 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Sep 2020.
- 28 Jun 2017 Planned initiation date changed from 1 Jan 2017 to 1 Sep 2017.